Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
- Status
- RECRUITING
- Phase
- PHASE1
Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab
- Status
- COMPLETED
- Phase
- PHASE2
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
- Status
- COMPLETED
- Phase
- N/A
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early Breast Cancer.
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
- Status
- COMPLETED
- Phase
- PHASE3
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- COMPLETED
- Phase
- PHASE2